Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080
This study is recruiting at 14 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Breast Cancer Metastatic
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Ovarian Cancer
- CCNE1 Amplification
- Solid Tumor
- Advanced Cancer
- Metastatic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Incyclix Bio
- Last updated on ClinicalTrials.gov
- April 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Florida Cancer Specialists · Orlando, FL
Georgia · 2
- Emory Winship Cancer Institute · Atlanta, GA
- Georgia Cancer Center at Augusta University · Augusta, GA
Indiana · 1
- Fort Wayne Medical Oncology and Hematology · Fort Wayne, IN
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- Karmanos Cancer Institute · Detroit, MI
New York · 1
- Roswell Park Cancer Institute · Buffalo, NY
North Carolina · 2
- Levine Cancer Institute (LCI)- Atrium Health · Charlotte, NC
- Duke Cancer Center/ DUMC · Durham, NC
Ohio · 1
- Gabrail Cancer Research Center · Canton, OH
Texas · 3
- Next Oncology · Dallas, TX
- UTSW Medical Center · Dallas, TX
- Next Oncology · Houston, TX
Washington · 1
- Northwest Medical Specialties, PLLC · Tacoma, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.